Glenmark Shares Fall 7% After US FDA Product Recall News

Glenmark Pharmaceuticals witnessed a sharp decline in its stock price after the US Food and Drug Administration (FDA) issued a product recall that shook investor confidence. The pharmaceutical major saw its shares tumble by nearly 7% on Wednesday, April 9, following reports of a Class-II recall involving 39 of its drug products shipped to the United States.

Why Did the Recall Happened?

The recall, initiated in March and officially classified as Class-II by the US FDA on April 8, 2025, primarily involved drugs nearing their expiry. According to the FDA website, most of the recalled products had reached or were close to reaching their expiration dates in March 2025. These products were manufactured at Glenmark’s facility in Pithampur, Madhya Pradesh.

A Class-II recall is issued when the use of a product may lead to temporary or medically reversible health effects. Though not considered as dangerous as a Class-I recall, it still requires swift corrective action. In this case, Glenmark will need to either withdraw the products from the US market or take necessary steps to ensure compliance.

What This Means for Glenmark?

While drug recalls are not uncommon in the pharmaceutical industry, the scale of this recall and the timing—given market volatility—added to investor concerns. The news also comes at a time when Glenmark is trying to strengthen its US business, which contributes a significant portion of its global revenues. Although the recall was linked mainly to product expiry, it raised questions about supply chain and inventory management practices.

Despite being routine in nature, such large-scale recalls may affect the company’s credibility in key markets like the US. Investors will be closely monitoring Glenmark’s next steps to address the situation and maintain regulatory compliance.

Glenmark Share Price Update

Following the recall announcement, Glenmark share price dropped to ₹1,376.35 on the BSE, marking a 4.35% intraday fall. Earlier in the day, the stock had slipped nearly 7% before recovering slightly. Overall, Glenmark shares have lost about 15% of their value so far in 2025.

Conclusion

Although the recall may not indicate a serious safety issue, its impact on investor sentiment has been immediate. As Glenmark works to navigate this challenge, how it manages the fallout will be key to restoring confidence and stabilising its share performance.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.